Category Archives: Uncategorized

Author, Screen Addiction Expert Coming to Eagle Ranch Sept. 20


Eagle Ranch is hosting a workshop with author, speaker and screen addiction expert, Melanie Hempe, on Friday, September 20, at its campus in Flowery Branch, Ga. Through her workshop Kids’ Brains & Screens, Hempe will address one of the most pervasive addiction issues facing children and families today. Hempe will provide practical solutions, including her Screenstrong™ approach to helping families manage children’s access and relationship to technology.


  • Open to Professionals and the Public

The workshop will offer 6 Continuing Education Units (CEUs) for therapeutic professionals, as designated by organizations including: LPCA-GA, NASW-GA, GAMFT. Parents and those who regularly interact and work with young people may also find the workshop of interest. The event takes place Friday, Sept. 20, 8:30 a.m.-3:30 p.m. at Eagle Ranch’s Flowery Branch campus, 5500 Union Church Road.

The cost for admission is $125 per participant, which includes the workshop, a catered lunch and snacks. Hempe will also have books and resources available at the event for an additional cost. For more information and a direct link to register on Eventbrite, visit http://www.EagleRanch.org/CEU.

Melanie Heme, a retired Registered Nurse, founded Families Managing Media after her journey in helping her oldest son break a video game addiction that began in middle school and led to him dropping out of college. She is the author of several books and guides on how families can manage screen addiction, video game habits and ore. The Screenstrong™ approach helps parents and professionals identify warning signs of trouble, offers tips for prevention and provides solutions for helping children and young adults who are in, or near, the stages of screen addiction. For more information on Hempe an Families Managing Media, visit ScreenStrong.com.

One of Georgia’s largest residential children’s programs, Eagle Ranch is designed to help make life better for children and families going through a crisis. Our integrated approach, built on Christian principles, models home life, emphasizes education, and incorporates multi-faceted counseling. For more information, visit EagleRanch.org.

Share article on social media or email:



Source link

Gulf Breeze Recovery on Methamphetamine Deaths


https://www.prweb.com/

Gulf Breeze Recovery Guest Room

“We found methamphetamine has profound harmful effects on the cardiovascular system and results in irreversible damage to the heart, raising the risk of a heart attack, sudden cardiac arrest, and heart failure,” states the co-lead author Chowdhury Abdullah

Autopsies don’t lie. They report the causes of death as well as what has caused damage or injury to the body.

Methamphetamine permanently harms the heart. It increases risks of heart attack and death. Autopsies definitively prove it. Through autopsies, doctors are getting a better understanding of how the damage occurs.

An August 1, 2019 article in U.S. News and World Report discussed findings researchers from Louisiana State University presented to the American Heart Association.”We found methamphetamine has profound harmful effects on the cardiovascular system and results in irreversible damage to the heart, raising the risk of a heart attack, sudden cardiac arrest, and heart failure,” postdoctoral fellow at LSU’s Health Sciences Center in Shreveport and study co-lead author Chowdhury Abdullah said in the heart association news release.

In comparison to samples from non-users, samples from the heart’s main pumping chamber (left ventricle) in meth users showed:

  • Increased deposits of collagen (stiff protein fibers) around the blood vessels.
  • Accumulation of collagen throughout the spaces between heart muscle cells.


Methamphetamine, commonly known as meth, is a stimulant that is absorbed in the digestive tract and is metabolized primarily in the liver. It speeds up systems in the body. Methamphetamine is sometimes legally prescribed as Desoxyn®(Methamphetamine Hydrochloride tablets) to treat attention deficit hyperactivity disorder or obesity.

Even when taken with medical supervision and used as prescribed, Desoxyn comes with warnings from the manufacturer of the possibility for serious cardiovascular events. The manufacturer of the medication warning states that sudden death has been reported in association with CNS (central nervous system) stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems, and that sudden deaths, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses for ADHD.

The Food and Drug Administration requires a black box warning on a prescription drug’s label that is designed to call attention to serious or life-threatening risks. The prescription black box warning for Desoxyn states:

Methamphetamine has a high potential for abuse. Particular attention should be paid to the possibility of subjects obtaining methamphetamine for non-therapeutic use or distribution to others, and the drug should be prescribed or dispensed sparingly. Misuse of methamphetamine may cause sudden death and serious cardiovascular adverse events

Those risks naturally multiply for individuals who are using methamphetamine recreationally that is produced and sold illegally with no controls for purity or dosage.

According to the 2017 National Survey on Drug Use and Health (NSDUH), approximately 1.6 million people (0.6 percent of the population) reported using methamphetamine in the past year, and 774,000 (0.3 percent) reported using it in the past month. The average age of new methamphetamine users in 2016 was 23.3 years old.

In 2017, Newsroom reported that illegal methamphetamine use was on the rise with U.S. veterans, as was heart failure associated with methamphetamine use. A study was completed of 9,588 veterans who were patients at the San Diego VA Medical center and were diagnosed with heart failure between 2005 and 2015. They found that meth use increased from 1.7 percent among VA heart failure patients in 2005 to 8 percent in 2015.

Other pertinent findings on the veterans who reported using methamphetamine were:

  • Meth users with heart failure, with an average age of 61, were notably younger than non-meth user heart failure patients, whose average age was 72 years.
  • Meth users were more likely to have psychiatric issues, such as depression and post-traumatic stress disorder, or PTSD.
  • Meth patients tended to visit the emergency department more often compared to heart failure patients without meth use.

Autopsies confirm, Methamphetamine is deadly.

About Gulf Breeze Recovery: Gulf Breeze Recovery, one of the holistic treatment centers in Florida, is changing the future of addiction treatment with the THRIVE® program focused on overcoming chronic relapse. Gulf Breeze Recovery’s THRIVE® program is a non-12-step approach and individualized designed for those who are looking for a drug and alcohol treatment program to produce a different and positive result. This non-12 step program allows you to drive beyond your addictions and promotes a new outlook on life. For more information about our program or to speak with an Addiction’s expert, please call 855-973-3551 or contact us.

Share article on social media or email:



Source link

$7,500 School Lounge Makeover® from California Casualty Will Give Nebraska Educators a Place of Their Own


https://mycalcas.com/community

NSEA’s Jennifer Dubois, California Casualty Field Marketing Manager Stephanie Whitmore, winner Mary Gregoski and NSEA’s Michelle Raphael

We are just so grateful that California Casualty thinks about educators.

“We will have a real place to meet, relax, and hold meetings – I can’t wait,” exclaimed English teacher Mary Gregoski, after learning she had won a $7,500 School Lounge Makeover® from California Casualty. Mary, also the school librarian, is in her 10th year teaching at Palmer Public School in Palmer, Nebraska.

Mary is dedicated to making a difference every day, teaching life skills, building relationships, and impacting students’ lives. “I focus on what I can do to prepare them for what’s coming next, and I’m always asking myself, ‘What’s best for the kids?’”

“The staff deserves this for all that they do, giving to students and the community,” said School Superintendent Joel Bohlken.

The school currently has no designated area where employees can eat lunch, visit and rejuvenate. Designers from EON Office Supplies will work with the staff to create a space with organized storage, new appliances and furniture, and soothing colors. The new lounge will be unveiled next month.

Mary applied for the makeover after a presentation from California Casualty’s Stephanie Whitmore during a Nebraska Education Association Leadership event. “We are just so grateful that California Casualty thinks about educators,” Mary added.

Palmer Public School is the 13th school to receive a School Lounge Makeover® from California Casualty. The contest was created in 2011 to provide educators a more conducive environment to take a break and share time. Find more information about California Casualty and its giving programs at https://mycalcas.com/community.

Founded in 1914, California Casualty provides auto and home insurance for educators, firefighters, peace officers and nurses across the country. Headquartered in San Mateo, California, with service centers in Arizona, Colorado and Kansas, California Casualty has been led by four generations of the Brown family. Learn more about California Casualty at http://www.calcas.com.

Share article on social media or email:



Source link

SOC Certified 3 Years in a Row


Longbow Advantage, the creator of Rebus Data Services, has re-certified their Rebus platform as SOC2 Type II compliant for the third year in a row.

SOC2 is provided by the American Institute of CPAs and reports on controls at a service organization relevant to security, availability, processing integrity, confidentiality, and privacy. SOC2 lets consumers know that their information is secure and available whenever they need it when working with SaaS and Cloud-Based services.

At Longbow, providing customers with the peace of mind that their data is safe, secure, and available whenever they need it, is critical. This is why being SOC2 certified is essential to any software solution that focuses on managing customer data.

Alex Wakefield, CEO at Longbow, says, “As Rebus experiences exponential customer and data growth, maintaining our SOC2 certification gives our customers the confidence that we take protecting their sensitive data seriously. It’s a personal top priority of mine.”

By being SOC2 reaffirms continuous commitment in giving customers peace of mind that their data is safe and secure.

Share article on social media or email:



Source link

Orion Pharmaceuticals Implements Genedata Biologics to Support New Large-Molecule R&D Initiative


As part of our strategy to expand our biopharmaceutical R&D operations, we are implementing Genedata as our central workflow backbone to streamline our large-molecule R&D processes

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced Orion Pharma, a globally operating Finnish pharmaceutical company, has licensed Genedata Biologics® to support their R&D in the areas of oncology, the central nervous system, and other medical indications.

“As part of our strategy to expand our biopharmaceutical R&D operations, we are implementing Genedata as our central workflow backbone to streamline our large-molecule R&D processes,” said Tim Holmström, Head of Biologics at Orion Pharma. “Genedata Biologics was the obvious choice because it is a proven, off-the-shelf enterprise platform that can be rapidly deployed across our organization. Also, collaborating with CROs is a key part of our strategy, so we require an open and scalable system able to capture and integrate all data generated by our CRO network. Finally, Genedata’s offering of Software-as-a-Service (SaaS) was an additional plus because we wanted a self-maintaining model that provides regular upgrades of new, innovative functionalities.”

Genedata Biologics enables Orion scientists to easily capture, process, and interpret all large-molecule R&D data and facilitate the design of antibodies. Further, it integrates all assay and analytics data to enable a comprehensive assessment of all drug candidates. The platform helps eliminate error-prone manual processes by providing a robust, standardized data repository that can be integrated with laboratory instrumentation. All molecule, sample, assay and analytics data, including developability and manufacturability data, are managed within one fully integrated system and are shared between different project teams and sites. The platform facilitates systematic and transparent decision-making to select drug candidates to be progressed through the development pipeline.

“We are very pleased that Orion, an innovative R&D-based pharmaceutical company, has selected Genedata Biologics as their workhorse platform for their biopharma R&D operations. By providing Orion with a backbone that covers their entire discovery pipeline in a single system, we help to increase the efficiency of their R&D processes and speed up decision making,” said Dr. Othmar Pfannes, CEO of Genedata. “Our technology, combined with Orion’s unique scientific approach, will bring cutting-edge therapeutics to patients faster and help them live better and longer lives.”

About Genedata

Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI from their R&D. Founded in 1997, Genedata is headquartered in Switzerland and has offices in Germany, the UK, Japan, and the US.

http://www.genedata.com

Follow Us on LinkedIn.

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Share article on social media or email:



Source link

Use of STRmix Expands in Universities


With jobs in forensic science expected to increase by nearly 20 percent by 2026, four U.S. universities now have STRmix™ – sophisticated forensic software that can resolve mixed DNA profiles previously thought to be too complex to interpret – as a planned or existing component of their student coursework.

The universities include: California State University, Sacramento; Eastern Kentucky University; George Washington University (GWU); and Marshall University (Graduate Program). They join two other universities, both in Canada, with STRmix™ in North America. Of interest, GWU plan to use STRmix™ in teaching a class in which students will be performing an internal validation of STRmix™ that will be the essential core of the class.

“With interest in forensic science careers on the rise, thanks in part to TV shows like CSI, it is only natural for universities to want to provide students with the ability to work in their labs with the same kind of forensic software they are likely to find themselves using in the workplace,” says John Buckleton DSc, FRSNZ, Forensic Scientist at the New Zealand Institute of Environmental Science and Research (ESR) and one of the developers of STRmix™.

According to the U.S. Bureau of Labor Statistics, employment of forensic science technicians is projected to grow 17 percent from 2016-2026, much faster than average for all occupations. Because the sector remains relatively small, however, competition for those jobs is expected to be very strong.

Beyond the universities, STRmix™ is now being used by the forensic labs of 46 U.S. agencies. That list includes federal agencies like the FBI and the Bureau of Alcohol, Tobacco, Firearms, and Explosives (ATF), state agencies such as those recently added in Massachusetts, South Carolina, and Colorado, and private companies like Bode Cellmark Forensics.

STRmix™ is also in various stages of installation, validation, and training in more than 60 other U.S. labs.

Dr. Buckleton attributes the widespread use of STRmix™ to its ability to significantly improve the usability of DNA. “More and more forensic labs worldwide are turning to STRmix™ to produce usable DNA evidence in a wide range of criminal cases,” he explains, noting that agencies using STRmix™ are reporting an increase of interpretable DNA in gun cases from about 40% to more than 70%. STRmix™ is also proving to be highly effective in sexual assault cases.

“Given the considerable resources invested in both resources and staff time to clear Sexual Assault Kit backlogs, forensic labs are quickly recognizing that STRmix™ is producing a much better return on investment by delivering a significantly higher rate of interpretable results,” Dr. Buckleton adds.

To date, STRmix™ has been used successfully in numerous U.S. court cases, including 28 successful admissibility hearings. Internationally, STRmix™ has been used to interpret DNA evidence in more than 120,000 cases since 2012.

STRmix™ is also being used in all nine state and territory labs in Australia and New Zealand, as well as 12 forensic labs in England, Scotland, Ireland, Finland, Dubai, Denmark, and Canada.

For more information about STRmix™ visit http://www.strmix.com.

Share article on social media or email:



Source link

Visikol Presents on Imaging 3D Cell Culture Models at the National Institute of Health


News Image

We recognize that for every assay there is a delicate balance between data density (i.e. images per model) and throughput

Visikol CEO Dr. Michael Johnson recently gave a talk at the National Institute of Health that was focused on how best to characterize 3D cell culture models. The inherent problem of characterizing 3D cell culture models is similar to regular tissues in that they are too thick and opaque to image through and therefore traditional wide-field or even confocal microscopy only tells you what is going on at the surface of these models. Because the surface cells are most exposed to compounds, nutrients, and oxygen, using this imaging data to extrapolate results can be very misleading as it only tells the story of the cells on the exterior and not the entire cell population. This bias has been detailed by Visikol through a recent application note titled 3D High Content Imaging of Optically-Cleared Microtissues for Screening Antiproliferative Cancer Drugs.

While 3D cell culture models could be embedded and sectioned for H&E and IHC, this process is laborious, low throughput and also greatly reduces an experiments sample size as many 3D cell culture models need to be embedded to acquire a single section from a single model. Additionally, based upon the polarity of a 3D cell culture model, this single slice might not be indicative of the phenotype of interest. Therefore, in this presentation Dr. Johnson goes into great detail on how to use tissue clearing to image the entirety of 3D cell culture models in multiple imaging channels without the need to ever section or remove the models from a well plate. Though this type of processing and confocal microscopy can reduce sample throughput compared to traditional wide-field imaging, it greatly increases the amount of data that can be generated per model, improves the accuracy of the conclusions that are made and also allows for the investigation of complex research questions.

“We see our Visikol® HISTO-M™ workflow as an easy-to-use pipeline for acquiring all of the information from 3D cell culture models but do recognize that for every assay there is a delicate balance between data density (i.e. images per model) and throughput,” described Dr. Johnson. Visikol currently sells the Visikol HISTO-M reagent and also offers end-to-end drug discovery services that leverage this technology combined with Visikol’s expertise in 3D cell culture, imaging and image analysis. Specifically, Visikol offers best-in-class 3D cell culture assays using this platform to address questions such as quantifying immune cell infiltration or assessing antibody therapeutic kinetics. If you are interested in discussing a 3D cell culture project or transitioning your 2D cell culture assay into a 3D cell culture assay reach out today.

CLICK TO WATCH TUTORIAL VIDEO

About Visikol

Visikol is a CRO focused on advanced drug discovery that is leading the fields of bio-imaging, bioinformatics and image analysis. We conduct end-to-end drug discovery services that include both 2D and 3D in vitro models and assays, 3D whole mount tissue imaging, digital pathology and custom drug discovery projects. Visikol offers a portfolio of drug discovery services ranging from 2D and 3D cell culture model and assay development to in vitro screening, animal tissue histology and automated image processing. The focus of these services is to transform tissues into images and ultimately into quantitative data sets that can be mined for actionable insights that help our Clients make more informed decisions during the drug discovery process. Additionally, Visikol manufactures and sells a suite of tissue clearing reagents and 3D immuno-labeling kits. These products allow researchers to easily and rapidly image whole tissues and 3D cell culture models in 3D instead of traditional 2D sectioning. For more information about Visikol or its services, please visit our website at visikol.com.

Share article on social media or email:



Source link

Fundraising as a Spiritual Journey


[In fundraising] you are embarking on a beautiful, Spirit-filled journey. Embrace this journey in a wholehearted way.

The Upper Room recently released a workbook edition of A Spirituality of Fundraising by Henri J. M. Nouwen and Nathan Ball. Nouwen, a best-selling spiritual writer and renowned scholar, innovated the way church and nonprofit leaders view fundraising in his original book, A Spirituality of Fundraising. This book changed tthe way people look at fundraising—from viewing it as a fear- and scarcity-driven task to seeing it as a spiritual journey. Nouwen writes, “Fundraising, first and foremost, is a form of ministry. It is a way of announcing our vision and inviting other people into our mission.”

Inspired by Nouwen’s vision, The Upper Room sought the expertise of Nouwen’s close friend and colleague Nathan Ball, asking him to write an accompanying workbook to aid fundraisers as they seek practical applications to Nouwen’s culture-shifting vision.

Ball, who met and shared community life with Henri Nouwen for over 10 years in Jean Vanier’s L’Arche communities in France and Canada, has more than 20 years of experience in fundraising-related roles.

“You may not have imagined that the task of fundraising would take you into a deeper relationship with yourself and God,” Ball writes. “You are embarking on a beautiful, Spirit-filled journey. Be grateful that you have Henri as your trustworthy guide. Give thanks for who you are, and embrace this journey in a wholehearted way.”

In A Spirituality of Fundraising Workbook Edition, Ball tackles the trepidations of fundraisers head-on with a 4-week how-to guide that includes questions for reflection and journaling, prompts for listening and meditation, and instructions for using the book in individual or group settings.

Nouwen and Ball invite all fundraisers—from church leaders to nonprofit volunteers—to embrace fundraising as a ministry and calling. Learn more about the workbook at UpperRoomBooks.com/FundraisingWorkbook.

About The Upper Room: The Upper Room is a global ministry dedicated to supporting the spiritual formation of Christians seeking to know and experience God more fully. From its beginnings in 1935 as a daily devotional guide, The Upper Room has grown to include publications, programs, prayer support, and other resources to help believers of all ages and denominations move to a deeper level of faith and service. To learn more, visit UpperRoom.org.

Share article on social media or email:



Source link

Clinerion Partners With Volv Global to Bring Treatment Earlier to Patients By Enhancing Diagnosis Search on Patient Network Explorer with inTrigue AI Algorithms


The partnership between Clinerion and Volv Global brings benefits to patients by combining Volv’s uniquely accurate cohort identification algorithms with Clinerion’s growing data network of hospitals around the world. The Volv and Clinerion partnership will deploy Volv’s inTrigue algorithms across many more hospitals and this will create tangible outcomes for patients who suffer from late diagnosis of between seven and 15 years, as well as from misdiagnosis and subsequent increased disease burden.

Volv’s inTrigue toolset offers enhanced clinical trial cohort selection and patient modeling for earlier diagnosis of rare and difficult to diagnose diseases. This supports rare disease communities who wish to be able to deploy effective early diagnostic signaling tools to help patients get earlier referral and confirmatory diagnosis.

Clinerion’s Patient Network Explorer leverages patient electronic health record (EHR) data to offer data intelligence for the acceleration of drug development, bringing innovative drugs earlier to patients. PNEx performs real-time patient data analytics on electronic medical records from Clinerion’s network of connected hospitals to offer solutions for clinical trial patient recruitment and generate data for real-world evidence. This process accelerates recruitment, the most prominent reason for trial delays, which result in avoidable suffering of patients and cost pharmaceutical companies sales revenues.

“Our partnership brings direct benefits to patients by combining Volv’s uniquely accurate cohort identification algorithms with Clinerion’s rapidly growing data network of hospitals around the world,“ says Christopher Rudolf, CEO of Volv. “We can jointly offer a wider reach for earlier diagnosis of rare diseases and enhanced clinical trial cohort selection through the inTrigue toolset and Clinerion’s PNEx.”

“AI integration is the next crucial step in the development of Patient Network Explorer,” says Ian Rentsch, Clinerion CEO. “Volv’s technologies will support us in harnessing the full power of the patient data in our hospital partners’ databases, to the betterment of patient outcomes throughout our network.”

Clinerion and Volv Global will launch their partnership at a special event at the Intelligent Health AI conference on September 11th-12th, in Basel, Switzerland. Please contact the press officers below if you would like to interview representatives of the two companies.

About Clinerion

Clinerion accelerates clinical research and medical access to treatments for patients. We use proprietary technologies for analysis of patient data from our global network of partner hospitals. Clinerion’s Patient Network Explorer radically improves the efficiency and effectiveness of clinical trial recruitment by offering data-driven protocol optimization, site feasibility evaluation and real-time patient search and identification to match patients to treatments. Our technology solution provides real-world evidence analytics for medical access. Clinerion facilitates the participation of partner hospitals in leading-edge, industry-sponsored trials and time savings in patient recruitment. We create innovative and disruptive fit-for-purpose solutions which enable pharmaceutical companies to shorten patient recruitment and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage real-time data from electronic health records which comply with international patient privacy and data security regulations. Clinerion is a global data technology service company headquartered in Switzerland.

Clinerion Website: http://www.clinerion.com

Clinerion’s Patient Network Explorer: http://www.clinerion.com/index/OverviewOurSolutions/ClinerionPatientNetworkExplorer

For more information, please contact:

Le Vin Chin

Director, Head of Marketing & Communications

Clinerion Ltd

Elisabethenanlage 11, 4051 Basel, Switzerland

Tel.: +41 61 865 60 54

media(at)clinerion(dot)com

About Volv Global SA

Volv is a Swiss is an AI and applied data science company based in Lausanne that produces solutions to address key critical issues in Healthcare for today and tomorrow. We develop differentiated Artificial Intelligence methodologies addressing a defined set of problems in healthcare, and have solutions that are targeted on rare diseases, personalised medicines and difficult-to-diagnose diseases with the product inTrigue. We also focus on cognitive disorders with inCognita, and are working on breakthrough management solutions for anti-microbial resistance and personalised oncology.

With unique tools, including some that are focused on finding weak signals in sparse, unstructured and structured data, Volv has a unique position in the Artificial Intelligence landscape. This allows us to focus on tangible economic and healthcare outcomes by differentiating patient cohorts and symptoms in a novel way that is required for the next generation of healthcare and the change in population dynamics that we see evolving. Volv’s toolsets are repeatable solutions that can fit into any data environment and allow rapid return on investment for our customers, building to longer term strategic partnerships.

Volv Global website: http://www.volv.global

For more information, please contact:

Jan Prins

Business Officer

Volv Global SA, Digital Health Hub, Building SE-A, Route de la Corniche 3, 1066 Epalinges, Switzerland

Tel.: +41 79 739 37 05

jprins(at)volv(dot)global

Share article on social media or email:



Source link

Cutting Tool Supplier WIDIA Products Group Joins the IBC Industrial Buying Group


WIDIA Products Group precision cutting tools

WIDIA Products Group is a leading manufacturer of precision cutting tools.

WIDIA is a global brand of innovative, high performance cutting tools and is a significant addition to IBC’s metalworking portfolio.

IBC is pleased to announce that WIDIA Products Group of Latrobe, Penn. has joined the IBC industrial buying group as a preferred supplier. WIDIA is a leading manufacturer of precision metal cutting tools utilized in CNC machining operations. Products include end mills, drills, taps, indexable milling cutters, turning tools, threading tools and tool holders. Authorized independent distributors within the IBC buying group now have access to WIDIA’s complete portfolio of precision engineered products and services to offer end users in the U.S. plus parts of Canada, Mexico and the Caribbean.

“WIDIA is a global brand of innovative, high performance cutting tools and is a significant addition to IBC’s metalworking portfolio,” stated Mark R. Higgins of IBC business development, relations and recruitment. “WIDIA is led by Jeff Kraez, an industry veteran, who has assembled an outstanding team to assist IBC members. Our ability to provide ‘world class’ solutions for end user customers has increased exponentially with WIDIA’s joining IBC.”

”WIDIA is excited about the opportunity to join forces with IBC and its members to help promote and grow the WIDIA brand,” said Jeff Kraez, general manager of WIDIA Americas. “Our position with current IBC distributors is already significant and we are confident that this partnership will only strengthen and prosper existing relationships as well as help to develop new ones.”

Preferred suppliers within the IBC buying group provide a wide range of industrial MROP products, safety products, janitorial supplies, bearing /power transmission products, electrical supplies and other products and services. Industrial buyers served by the IBC network of independent distributors represent the automotive, aerospace, power generation, food and beverage, medical, chemical and paper industries among others. In the U.S., it is estimated that independent distributors account for nearly two-thirds of all industrial supply chain sales.

For more information about WIDIA, please contact the company’s inside sales team by phone (800-979-4342) or email (w-na.service(at)widia(dot)com) or visit the company online at http://www.widia.com.

For more information about IBC, please contact Mark R. Higgins, Business Development, Relations and Recruitment via email at mhiggins(at)industrialbuyers(dot)com or visit http://www.industrialbuyers.com.

About WIDIA Products Group

WIDIA products and services have defined innovation in the metal cutting industry for more than 90 years — from the world’s first patent for carbide indexable inserts to the development of the world’s first coated grades. The WIDIA brand offers a complete portfolio of precision-engineered products and custom solution services. With thousands of milling, turning, holemaking and tooling systems products available through a worldwide network of authorized distributor partners, you’ll find everything you need from one single source. Learn more at http://www.widia.com.

About IBC

IBC is a robust and dynamic alliance of industrial, bearing and power transmission, electrical and subassembly independent distributor members with locations throughout the U.S. plus parts of Canada, Mexico and the Caribbean. The organization provides end user customers with multiple plant locations a streamlined and cost-effective purchasing source for national and regional contracts. IBC provides its independent distributor members and preferred suppliers with the tools, resources, and market access needed to thrive in today’s competitive marketplace, including a unique collaboration forum. IBC is a Hispanic Minority Business Enterprise (MBE) certified by the National Minority Supplier Development Council (NMSDC).

Share article on social media or email:



Source link